Cyclosporine
Treatment for Eczema
Typical Dosage: 2.5-5 mg/kg/day orally
Effectiveness
88%
Safety Score
30%
Clinical Trials
29
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
2.5-5 mg/kg/day orally
Time to Effect
1-2 weeks
Treatment Duration
3-12 months
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$1,500
Side Effect Mgmt:$300
Total Annual:$3,800
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$80,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$5,067
Cost per Remission
$7,600
Cyclosporine Outcomes
for Eczema
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+50%
Common Side Effects
Nephrotoxicity
+30%
Hypertension
+15%
Headache
+15%
Paresthesia
+12%
Hypertrichosis
+8%
Gingival hyperplasia
+7%
Increased risk of infection
+8%
Active Clinical Trials
3 active trials recruiting for Cyclosporine in Eczema
National Register of Moderate and Severe Adult Atopic Dermatitis
NCT06313333RECRUITING
1.5K participants
OBSERVATIONAL
Brescia, Italy
Started: Jun 15, 2020
Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy
NCT05674695RECRUITING
2.5K participants
OBSERVATIONAL
Badalona, Spain +8 more
Started: Jan 1, 2019
Microbiome in Atopic Dermatitis Under Systemic Therapy
NCT05099315RECRUITING
600 participants
OBSERVATIONAL
Berlin, Germany
Started: Oct 1, 2019
Completed Clinical Trials
12 completed trials for Cyclosporine in Eczema
Reversal of Epidermal Phenotype in Severe Atopic Dermatitis With Cyclosporine Therapy
NCT01149759COMPLETEDNA
9 participants
INTERVENTIONAL
New York, United States
Started: Jun 1, 2010
Prednisolone vs. Ciclosporine in Severe Atopic Eczema
NCT00445081COMPLETEDPHASE4
66 participants
INTERVENTIONAL
Graz, Austria +4 more
Started: Mar 1, 2007
Verification Study of Ciclosporin for Atopic Dermatitis
NCT00232076COMPLETEDPHASE3
INTERVENTIONAL
Started: May 1, 2004
Long-term Study of Ciclosporin for Atopic Dermatitis
NCT00232063COMPLETEDPHASE3
INTERVENTIONAL
Started: May 1, 2004
Study of Methotrexate Efficacy Versus Cyclosporine in Moderate to Severe Atopic Dermatitis Patients
NCT00809172COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Lyon, France
Started: Dec 1, 2008
A Study Evaluating the Safety and Efficacy of QGE031 in Atopic Dermatitis Patients
NCT01552629COMPLETEDPHASE2
22 participants
INTERVENTIONAL
Vienna, Austria +3 more
Started: Jan 5, 2012
Photophoresis Versus Ciclosporine in Severe Atopic Dermatitis
NCT02226068COMPLETEDNA
20 participants
INTERVENTIONAL
Started: Jun 1, 2002
Real-world Experience on the Use of Upadacitinib in the Treatment of Moderate-severe Adult Atopic Dermatitis (ERUDA)
NCT05989932COMPLETED
146 participants
OBSERVATIONAL
Roma, Italy
Started: Dec 15, 2021
Topical Solution for the Treatment of Atopic Dermatitis
NCT02865356COMPLETEDPHASE2
36 participants
INTERVENTIONAL
Badalona, Spain +8 more
Started: Sep 1, 2016
Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis
NCT06509243COMPLETEDNA
132 participants
INTERVENTIONAL
Zabrze, Poland
Started: Feb 10, 2023
Standardized Time- and Score-oriented Treatment of Moderate and Severe Atopic Dermatitis
NCT00148746COMPLETEDNA
INTERVENTIONAL
Dresden, Germany
Started: May 1, 2004
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine
NCT05149313COMPLETEDPHASE3
331 participants
INTERVENTIONAL
Graz, Austria +47 more
Started: Dec 23, 2021
Showing 20 of 30 total trials